Basic Information
Vimkunya
Regulatory Information
EMEA/H/C/005470
Authorised
February 28, 2025
January 30, 2025
March 24, 2025
Company Information
Denmark
Philip Heymans Alle 3 2900 Hellerup
Bavarian Nordic A/S
Drug Classification
Additional Monitoring
Active Substances Detail
Chikungunya virus (CHIKV) virus-like particle (VLP) proteins (capsid protein (C) and envelope proteins E1 and E2) derived from CHIKV Senegal strain 37997 produced in human embryonic kidney cells by recombinant DNA technology, adsorbed on aluminium hydroxide, hydrated
EMA Resources
Detailed Information
Overview Summary
Vimkunya is a vaccine used to protect adults and adolescents from 12 years of age against chikungunya. Chikungunya is a disease caused by chikungunya virus, which is transmitted to humans by infected mosquitoes. Vimkunya contains proteins from a chikungunya virus strain called Senegal strain 37997 (capsid protein and envelope proteins E1 and E2). These proteins are assembled into virus-like particles that are not infectious. The vaccine cannot cause chikungunya in people who receive the vaccine.